Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer

BMC Cancer

Table 1 Basic characteristics of enrolled patients (N = 48)

	N	%
Age, median, years (range)	52 (28–81)
Sex
Female	48	100.0%
Staging (AJCC 7th Edition)
Stage IV	48	100.0%
Performance status (ECOG)
0–1	41	85.4%
≥ 2	7	14.6%
Receptor status
ER and/or PR positive	35	72.9%
HER-2/neu positive	23	47.9%
Triple-negative (ER/PR/HER2)	8	16.7%
Number of metastases
Single metastasis	16	33.3%
≥ 2 metastases	32	66.7%
Site of distant metastasis at study enrollment
Bone	35	72.9%
Liver	18	37.5%
Distant lymph nodes	17	35.4%
Lung	16	33.3%
Brain	7	14.6%
Pleura	6	12.5%
Visceral metastasis†	34	70.8%
Nonvisceral metastasis	14	29.2%

Abbreviations: AJCC, American Joint Committee on Cancer; ECOG, Eastern Cooperative Oncology Group. SD: standard deviation; CI: confidence interval. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PFS: progression-free survival; OS: overall survival
†Visceral sites include the lungs, liver, brain, adrenal glands, and pleura (with or without effusion). Nonvisceral sites were defined as the breast, lymph nodes, chest wall, bones, and skin

ISSN: 1471-2407